192 related articles for article (PubMed ID: 17897085)
1. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
2. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
3. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
[TBL] [Abstract][Full Text] [Related]
6. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
7. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
[TBL] [Abstract][Full Text] [Related]
8. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.
Huang M; Wang Y; Gu J; Yang J; Noel K; Mitchell BS; Schramm VL; Graves LM
Leuk Res; 2008 Aug; 32(8):1268-78. PubMed ID: 18279955
[TBL] [Abstract][Full Text] [Related]
9. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
Robak T; Lech-Maranda E; Korycka A; Robak E
Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
11. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
[TBL] [Abstract][Full Text] [Related]
12. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
13. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
Furman RR; Hoelzer D
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
[TBL] [Abstract][Full Text] [Related]
14. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
15. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
16. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
Ravandi F; Gandhi V
Expert Opin Investig Drugs; 2006 Dec; 15(12):1601-13. PubMed ID: 17107284
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
[TBL] [Abstract][Full Text] [Related]
18. The transition state analog inhibitor of Purine Nucleoside Phosphorylase (PNP) Immucillin-H arrests bone loss in rat periodontal disease models.
Deves C; de Assunção TM; Ducati RG; Campos MM; Basso LA; Santos DS; Batista EL
Bone; 2013 Jan; 52(1):167-75. PubMed ID: 23026564
[TBL] [Abstract][Full Text] [Related]
19. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
Kicska GA; Long L; Hörig H; Fairchild C; Tyler PC; Furneaux RH; Schramm VL; Kaufman HL
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4593-8. PubMed ID: 11287638
[TBL] [Abstract][Full Text] [Related]
20. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
Banti S; Miller PJ; Parker CD; Ananth SL; Horn LL; Babu YS; Sandhu JS
Int Immunopharmacol; 2002 Jun; 2(7):913-23. PubMed ID: 12188033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
